Not necessarily. A company with a drug already on a fast track, and demonstrably better than the current standard of care, may not see the necessity of using the PRV to save possibly a handful of months when a very large company had a far greater financial imperative to buy it.
Not necessarily. A company with a drug already on a fast track,...
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)